Pulmonx (NASDAQ:LUNG) Announces Earnings Results

Pulmonx (NASDAQ:LUNG) announced its quarterly earnings data on Wednesday. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07, Zacks reports. The company had revenue of $18.85 million for the quarter, compared to the consensus estimate of $17.54 million. Pulmonx had a negative return on equity of 46.61% and a negative net margin of 80.46%. During the same period in the previous year, the business earned ($0.42) EPS. Pulmonx updated its FY 2024 guidance to EPS.

Pulmonx Stock Performance

Pulmonx stock traded up $0.44 during mid-day trading on Friday, reaching $9.82. 999,827 shares of the company’s stock were exchanged, compared to its average volume of 562,070. The firm has a market capitalization of $378.46 million, a PE ratio of -6.38 and a beta of 0.66. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30. The business’s fifty day simple moving average is $8.58 and its 200 day simple moving average is $10.70. Pulmonx has a one year low of $7.11 and a one year high of $14.84.

Insider Activity

In other Pulmonx news, CEO Glendon E. French III sold 20,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.60, for a total value of $292,000.00. Following the transaction, the chief executive officer now directly owns 1,121,344 shares in the company, valued at $16,371,622.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, General Counsel David Aaron Lehman sold 4,351 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $9.06, for a total value of $39,420.06. Following the completion of the transaction, the general counsel now directly owns 145,488 shares in the company, valued at $1,318,121.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Glendon E. French III sold 20,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.60, for a total transaction of $292,000.00. Following the transaction, the chief executive officer now owns 1,121,344 shares of the company’s stock, valued at $16,371,622.40. The disclosure for this sale can be found here. Insiders sold a total of 39,032 shares of company stock valued at $469,012 in the last ninety days. 5.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Stifel Nicolaus raised their price target on shares of Pulmonx from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $17.00 target price on shares of Pulmonx in a research report on Wednesday, April 3rd. Canaccord Genuity Group reduced their price objective on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating for the company in a report on Thursday. Wells Fargo & Company restated an “equal weight” rating and issued a $14.00 target price (down previously from $16.00) on shares of Pulmonx in a report on Friday, February 23rd. Finally, Citigroup boosted their price objective on Pulmonx from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.33.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.